DRRX (DURECT) צמיחת רווחי EPS רבעונית
The protection of unique molecules and strict FDA oversight create a niche monopoly for DURECT Corporation (DRRX). Quarterly EPS variation demonstrates revenue dynamics, where 39.50 represents the current metric. Profit growth relies on a stable staff of biochemists and the expansion of larsucosterol within Phase III trials to capture the market for acute liver pathology therapies.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_DRRX_-_DURECT-Corporation_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "DURECT (DRRX): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 27.09.2025 | 👁️GURU.Markets👁️")
DRRX (DURECT): פילוחים אנליטיים ודוחות לפי אינדיקטורים
This indicator measures the dynamics of net earnings per share, neutralizing time gaps between reporting periods to identify the actual pace of business scaling. By analyzing the quarterly change in earnings per share, an investor assesses the capitalization efficiency of DURECT Corporation (DRRX) joint developments in epigenetics and liver disease therapy, which confirms the commercial viability of its strategic partnerships.
